We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | NASDAQ:IOVA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.81 | 6.29% | 13.69 | 11.50 | 26.00 | 13.8799 | 13.30 | 13.46 | 4,292,824 | 05:00:12 |
Prospectus Supplement No. 1 (To Prospectus Dated July 31, 2017) |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-212373
|
IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
This Prospectus Supplement supplements, and should be read in conjunction with, our Prospectus included in Post-Effective Amendment No. 1 to Registration Statement on Form S-3 (Registration No. 333-212373) dated July 31, 2017 (the “ Prospectus ”). This Prospectus Supplement must be delivered with the Prospectus.
The information in the Prospectus in the section titled “Selling Stockholders” is amended by this Prospectus Supplement to reflect the transfer by OrbiMed Partners II, L.P. of 877,700 shares of our restricted common stock and 1,030,726 uncertificated shares of our restricted Series B Convertible Preferred Stock to OrbiMed Partners Master Fund Limited.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus Supplement. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is January 9, 2018.
SELLING STOCKHOLDERS
SUPPLEMENTAL INFORMATION
The table beginning on page 6 of the Prospectus in the section titled “Selling Stockholders” is amended as follows.
The table is hereby revised to reflect the following transfers: (i) OrbiMed Partners II, L.P. transferred 877,700 shares of our restricted common stock to OrbiMed Partners Master Fund Limited; and (ii) OrbiMed Partners II, L.P. transferred 1,030,726 uncertificated shares of our restricted Series B Convertible Preferred Stock to OrbiMed Partners Master Fund Limited. The beneficial ownership information for the selling stockholder listed below is as of January 9, 2018.
Beneficial Ownership
Before Offering |
Number of Shares |
Beneficial Ownership
After Offering |
||||||||
Selling Stockholder | Number of Shares | Percent | Being Offered | Number of Shares | Percent | |||||
OrbiMed Partners Master Fund Limited | 4,210,526(2)(3) | 5.80% | 4,210,526 | 0 | - |
(2) | Shares of the Company are held by OrbiMed Partners Master Fund Limited (“OP Master”). OrbiMed Capital LLC (“Capital”) is the investment adviser for OP Master. Samuel D. Isaly (“Isaly”) is the managing member of, and owns a controlling interest in, Capital. Each of Capital and Isaly disclaims beneficial ownership of the shares held by OP Master, except to the extent of its or his pecuniary interest therein, if any. |
(3) | Includes 2,273,726 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock. |
1 Year Iovance Biotherapeutics Chart |
1 Month Iovance Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions